AI-Based Drug Interaction Analysis for Safer Medication

Abstract

Drug-Drug interactions (DDIs) continue to be an important issue in healthcare, particularly when patients are on multiple drugs for chronic conditions. Such interactions not only lessen the potency of drugs but may also lead to adverse effects or even toxicity. Most of the current detection mechanisms rely on rule-based methods and medical resort databases that generally do not discover intricate or unfamiliar interactions. The present work puts forward an AI-Powered Drug Interaction Monitoring System that employs deep learning for the estimation of interactions of drug pairs. Chemical characteristics are first obtained with the use of RDKit and then processed with a deep neural network model. The tool offers instantaneous predictions via a web platform and makes medication safety better by giving highly accurate predictions.

Introduction

This study presents an AI-Based Drug Interaction Analysis System designed to predict potential drug-drug interactions (DDIs) and improve medication safety. As healthcare increasingly relies on polypharmacy (the simultaneous use of multiple medications), the risk of harmful drug interactions has grown significantly. These interactions can reduce treatment effectiveness, cause adverse side effects, lead to overdoses, or even result in life-threatening conditions. Therefore, early detection of DDIs is essential for patient safety and effective healthcare delivery.

Traditional DDI detection systems depend on rule-based databases and clinical studies to identify known interactions. While effective for established drug combinations, these methods struggle to detect unknown or complex interactions among newly developed drugs and require continuous manual updates. The rapid growth of pharmaceutical compounds has made traditional approaches increasingly difficult to maintain.

To address these limitations, the proposed system uses Artificial Intelligence (AI) and deep learning to automatically identify interaction patterns from large biomedical datasets. Drug molecules are represented using chemical descriptors and molecular fingerprints generated through RDKit, a cheminformatics tool. These molecular features are then processed by deep neural networks trained to classify drug pairs as interacting or non-interacting.

Main Objectives

• Develop a deep learning framework for accurate drug interaction prediction.
• Extract meaningful molecular features from drug structures using cheminformatics tools.
• Improve prediction performance compared to traditional machine learning methods.
• Provide a scalable, real-time, and user-friendly web platform for healthcare professionals.

Key Results

Literature Review Highlights

Previous research progressed from:

1. Rule-based systems using pharmaceutical databases.
2. Traditional machine learning models such as Support Vector Machine, Random Forest, and Logistic Regression.
3. Deep learning approaches capable of learning complex molecular relationships automatically.
4. Advanced methods using Graph Neural Networks, molecular fingerprints, attention mechanisms, transformer models, and multimodal biomedical data integration.

Researchers have also emphasized the importance of explainable AI, scalability, and integration with clinical decision-support systems.

Proposed Methodology

The system follows a modular architecture consisting of:

• Data collection and cleaning
• Molecular feature extraction
• Deep learning-based prediction
• Web-based user interface

Prediction Workflow

1. User enters two drug names.
2. Drug structures are retrieved as SMILES strings.
3. RDKit extracts molecular descriptors and fingerprints.
4. A trained deep learning model analyzes these features.
5. The system predicts whether the drugs interact and returns results through a web interface.

System Components

• Feature Extraction Engine: Converts molecular structures into numerical representations.
• Prediction Engine: Uses deep neural networks to classify drug pairs as interacting or non-interacting.
• Security Module: Protects user data through encryption and secure API communication.
• Performance Optimization: Supports large datasets and delivers predictions within seconds.

Implementation

The platform uses:

• Frontend: HTML, CSS, and JavaScript for an interactive user interface.
• Backend: FastAPI for RESTful APIs and prediction services.
• Machine Learning Layer: Deep learning models for DDI prediction.
• Database Layer: Stores drug datasets, molecular information, and prediction records.

Conclusion

This paper has developed an AI-based Drug-Drug Interaction (DDI) Analysis System, which is capable of raising medication safety by accurately predicting potential drug interactions. The system utilizes a Deep Neural Network (DNN) that has been trained on various biomedical datasets comprising drug interaction records, side effects, and molecular structure information that allow it to uncover complex drug-drug relationships. The test results illustrate the model\'s ability to produce strong and consistent performance reflected by high levels of accuracy precision recall, and F1 score which demonstrate the model\'s competency in identifying both interacting and non-interacting drug pairs. Besides, the system is able to generalize well when tested with the new drug combinations, which proves its robustness as well as practical implementation. Use of Explainable AI features, alternative drug suggestions, lifestyle-based interaction analysis, and real-time alert mechanisms, in addition to the very accurate predictions, enable the system to organically thrive both in usability and in its position as a real-world player. In contrast to conventional rule-based approaches, the proposed deep learning-based method delivers better flexibility and the capability of discovering concealed interaction patterns. Nevertheless, the performance of this system relies on the quality as well as the diversity of the training set and therefore predictions on drugs that are newly introduced or very rare might be in need of additional verification. Works in the future may be directed toward the usage of larger and more diverse datasets, upgrading the model architecture, and the inclusion of more clinical parameters with the purpose to increase the prediction accuracy and reliability even more. In short, the developed system can act as a highly efficient and intelligent support tool for drug interaction analysis decisions hereby facilitating both safer medication interventions and better healthcare outcomes.

References

[1] N. P. Tatonetti, P. P. Ye, R. Daneshjou, and R. B. Altman present a method aimed at predicting drug effects and their interactions in a data-driven manner (Science Translational Medicine, vol. 4, no. 125, pp. 125-131, 2012). [2] D. Wishart et al. present the DrugBank database, which is a comprehensive resource for supporting in-silico drug discovery and research (Nucleic Acids Research, vol. 46, no. D1, pp. D1074D1082, 2018). [3] In their research, authors L. Zhang, J. Liu, and X. Chen describe a method that is based on deep neural networks for predicting drug-drug interactions (Bioinformatics, vol. 35, no. 14, pp. 239-247, 2019). [4] According to Y. Ryu, H. Kim, and J. Lee, deep learning has a major influence on improving the prediction of drug-drug and drug-food interactions (Proceedings of the National Academy of Sciences, vol. 115, no. 18, pp.E4304-E4311, 2018). [5] J. Cheng and L. Zhao have found that machine learning techniques, when combined with molecular fingerprinting, can be very effective in predicting drug interactions (Journal of Biomedical Informatics, vol. 89, pp. 168177, 2019). [6] G. Landrum, \"RDKit: Open-source cheminformatics software, \" 2020. [Online]. Available: https://www.rdkit.org [7] T. Chen and C. Guestrin, \"XGBoost: A scalable tree boosting system, \" in Proc. 22nd ACM SIGKDD Int. Conf. Knowledge Discovery and Data Mining, San Francisco, USA 2016. [8] M. Zitnik, M. Agrawal, and J. Leskovec present a model for the prediction of polypharmacy side effects using graph convolutional networks (Bioinformatics, vol. 34, no. 13, pp. i457i466, 2018). [9] Authors Y. Xu, S. Dai, and X. Zhou propose the use of graph neural networks to predict drug-drug interactions (IEEE/ACM Transactions on Computational Biology and Bioinformatics, vol. 18, no. 3, pp. 10191030, 2021). [10] I. Goodfellow, Y. Bengio, and A. Courville, Deep Learning. Cambridge, MA, USA: MIT Press, 2016. [11] F. Chollet, \"Keras: Deep learning library for Python, \" 2015. [Online]. Available: https://keras.io [12] M. Abadi et al. \"TensorFlow: A system for large-scale machine learning, \" in Proc. 12th USENIX Symposium on Operating Systems Design and Implementation, Savannah, USA, 2016. [13] J. Brownlee, Deep Learning for Drug Discovery. Machine Learning Mastery, 2020. [14] A. Vamathevan et al. \"Applications of machine learning in drug discovery and development, \" Nature Reviews Drug Discovery, vol. 18, pp. 463-477, 2019. [15] X. Li, Y. Zhou, and H. Wang, \"Artificial intelligence in healthcare: Drug interaction prediction using deep learning models, \" [16] IEEE Access, vol. 8, pp. 122345-122356, 2020.

Copyright

Copyright © 2026 Mrs. B. Haritha , Lakshmi Rupanjali Gongati, Hema Priya Addanki, Brahmani Gogireddy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.